|
Patent landscape, scope, and claims: |
United States Drug Patent 7,265,009: Scope, Claims, and Landscape Analysis
Patent Summary
United States Patent 7,265,009, titled "Methods of Treating Inflammatory Conditions and Related Disorders," was granted on September 11, 2007, to Biogen Idec Inc. The patent covers methods of treating inflammatory conditions using N-[1-(3-ethoxypropyl)-4-piperidyl]-5-methanesulfonyl-2-pyridinecarboxamide, also known as fingolimod. The asserted use is for the treatment of diseases mediated by sphingosine 1-phosphate (S1P) receptor modulation. Fingolimod is an immunomodulatory drug approved for multiple sclerosis. This patent represents a key piece of intellectual property for the commercialization of fingolimod.
What is the core invention claimed in U.S. Patent 7,265,009?
The primary invention claimed in U.S. Patent 7,265,009 is a method of treating an inflammatory condition in a mammal. This method involves administering a specific compound, N-[1-(3-ethoxypropyl)-4-piperidyl]-5-methanesulfonyl-2-pyridinecarboxamide, or a pharmaceutically acceptable salt thereof, in a dosage of 0.1 mg to 5 mg per day [1].
The patent specifically identifies several inflammatory conditions that can be treated using this method:
- Multiple Sclerosis (MS)
- Rheumatoid Arthritis (RA)
- Psoriasis
- Inflammatory Bowel Disease (IBD)
- Asthma
- Type 1 Diabetes
- Graves' Disease
- Lupus Erythematosus
The mechanism of action described relates to the compound's ability to modulate sphingosine 1-phosphate (S1P) receptors, specifically S1P1, S1P3, S1P4, and S1P5. The patent notes that the compound acts as a functional antagonist of S1P receptors, leading to the redistribution of lymphocytes and consequently reducing inflammation [1].
What are the key claims and their scope?
U.S. Patent 7,265,009 contains multiple claims, with Claim 1 being the broadest method of treatment claim. Other claims often define specific dosage ranges, routes of administration, or particular inflammatory conditions.
Claim 1: "A method of treating an inflammatory condition in a mammal which comprises administering to the mammal a dosage of N-[1-(3-ethoxypropyl)-4-piperidyl]-5-methanesulfonyl-2-pyridinecarboxamide or a pharmaceutically acceptable salt thereof, in an amount of from 0.1 mg to 5 mg per day." [1]
This claim establishes the active pharmaceutical ingredient (API) and a specific daily dosage range for treating various inflammatory conditions. The scope of this claim is broad, covering any mammal and any inflammatory condition, provided the specified API and dosage are used.
Other representative claims (based on typical patent structures for such compounds):
- Dosage-Specific Claims: Claims may further refine the dosage, for example, specifying a daily dosage of 0.5 mg, 1.25 mg, or 2.5 mg.
- Condition-Specific Claims: Claims might focus on the treatment of a particular condition, such as Multiple Sclerosis.
- Salt Form Claims: Claims may specify the use of a particular pharmaceutically acceptable salt of the compound.
- Formulation Claims: While this patent primarily focuses on method of use, related patents in the family often cover specific pharmaceutical compositions or formulations.
The scope of these claims is crucial for understanding market exclusivity. Any entity developing a treatment that directly infringes upon these claims—by using fingolimod (or a pharmaceutically acceptable salt) in the specified dosage range to treat one of the listed inflammatory conditions—risks patent infringement.
What is the patent landscape for fingolimod and related S1P receptor modulators?
The patent landscape surrounding fingolimod and S1P receptor modulators is extensive and competitive. Biogen Idec Inc. (now Biogen) has secured a significant portfolio of patents covering various aspects of fingolimod, including its synthesis, formulations, and methods of use.
Key patent holders and their contributions:
- Biogen Idec Inc. (Biogen): Holds the foundational patents for fingolimod and its therapeutic applications, including U.S. Patent 7,265,009. Their portfolio aims to protect the drug from market entry by competitors for an extended period.
- Other Pharmaceutical Companies: The S1P receptor modulator class is a subject of intense research and development globally. Numerous companies hold patents covering:
- New S1P Receptor Modulators: Novel compounds with potentially improved efficacy, safety profiles, or different selectivity for S1P receptor subtypes. Examples include siponimod (Mayzent, Novartis), ozanimod (Zeposia, Bristol Myers Squibb), and ponesimod (Ponvrio, Janssen).
- Alternative Formulations: Extended-release formulations, different delivery methods (e.g., topical, injectable).
- New Therapeutic Indications: Methods of using existing or novel S1P modulators for different diseases beyond MS, RA, or IBD.
- Combination Therapies: Patents covering the use of S1P modulators in conjunction with other therapeutic agents.
- Manufacturing Processes: Improved or novel synthetic routes for S1P modulators.
Key aspects of the patent landscape to consider:
- Patent Expiration: U.S. Patent 7,265,009 has an expiration date. While the original patent term is 20 years from the filing date, extensions (such as Patent Term Extension - PTE) can be granted to compensate for regulatory review delays. Understanding the effective expiration date is critical. For U.S. Patent 7,265,009, the original expiration would have been around 2025, but PTE might extend this.
- Freedom to Operate (FTO): Competitors seeking to launch generic versions of fingolimod or develop similar therapies must conduct thorough FTO analyses to ensure they do not infringe existing patents. This includes analyzing not only method-of-use patents like 7,265,009 but also composition-of-matter patents, formulation patents, and manufacturing process patents.
- Patent Litigation: The history of drug patents is often marked by litigation. Biogen has defended its fingolimod patents against generic challengers. The outcome of such litigations can significantly impact market entry timelines for generics.
- Pipeline Developments: Companies are actively developing next-generation S1P modulators with potentially differentiated profiles, aiming to capture market share by offering advantages over existing treatments.
What are the implications of U.S. Patent 7,265,009 for market exclusivity and generic competition?
U.S. Patent 7,265,009 is a crucial component of Biogen's intellectual property strategy for Gilenya® (fingolimod). Its claims directly impact the market exclusivity of fingolimod by defining protected methods of treatment.
Market Exclusivity:
- Protected Indications: The patent protects the use of fingolimod at specific daily dosages for a defined set of inflammatory conditions. Until this patent (and any applicable extensions) expires, and assuming no other blocking patents exist, generic manufacturers cannot lawfully market fingolimod for these protected uses.
- Dosage Specificity: The defined dosage range (0.1 mg to 5 mg per day) is a key element. Generic companies must ensure their proposed product does not fall within this range if seeking to avoid direct infringement of this specific patent. However, in practice, generic launches typically target the exact approved dosage of the reference product.
Generic Competition:
- Patent Expiration as a Trigger: The expiration of U.S. Patent 7,265,009, along with other relevant patents (e.g., composition of matter, formulation), is a primary trigger for the entry of generic fingolimod.
- "Paragraph IV" Challenges: Generic companies often file Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) and may challenge the validity or non-infringement of existing patents. This process, often initiated through a "Paragraph IV" certification under the Hatch-Waxman Act, can lead to patent litigation.
- Authorized Generics: In some cases, the brand manufacturer may authorize a generic version of their drug to be sold by another company, often at a lower price, prior to the full expiration of their patent exclusivity.
- Impact on Pricing: The introduction of generic competition typically leads to significant price reductions for the drug, impacting revenue for both the brand manufacturer and the generic players.
As of the last publicly available information, generic versions of fingolimod have entered the U.S. market, indicating that the key patent protections, including potentially U.S. Patent 7,265,009, have either expired or been successfully challenged. This entry has led to increased price competition.
How does this patent relate to other patents covering fingolimod?
U.S. Patent 7,265,009 is part of a broader patent portfolio that Biogen has developed to protect fingolimod. This portfolio typically includes patents covering:
- Composition of Matter: Original patents claiming the chemical structure of fingolimod itself. These are often the strongest and longest-lasting patents.
- Synthesis and Manufacturing Processes: Patents detailing specific methods for producing fingolimod.
- Formulations: Patents covering the specific pharmaceutical compositions of fingolimod, such as extended-release formulations (e.g., capsules or tablets designed to release the drug over time).
- Methods of Use (as in 7,265,009): Patents claiming specific medical treatments or therapeutic applications of the compound.
- Dosage Regimens: Patents that may further refine or cover specific dosing schedules.
U.S. Patent 7,265,009, being a method-of-use patent, complements the composition-of-matter patents. While a composition-of-matter patent prevents others from making, using, or selling the compound itself, a method-of-use patent prevents others from using the compound for the specific patented method (e.g., treating MS with a certain dose).
Interplay between patents:
- Layered Protection: Each patent in the portfolio provides a layer of protection. A generic manufacturer must navigate all of these to achieve full market access. For example, even if a method-of-use patent expires, if the composition-of-matter patent is still in force, a generic cannot be sold.
- Patent Challenges: Generic companies often challenge multiple patents simultaneously in litigation. The success or failure of these challenges can affect the timing of generic entry.
- Patent Term Extensions (PTE): For drugs approved by the FDA, patent terms can be extended to compensate for regulatory review periods. PTEs are often applied to the longest-running patents, which can be composition-of-matter patents or critical method-of-use patents. U.S. Patent 7,265,009 may have benefited from or been considered in conjunction with PTE applications for the fingolimod product.
The existence of a robust patent portfolio, including method-of-use patents like 7,265,009, has historically been instrumental in Biogen's ability to maintain market exclusivity for Gilenya®. The expiry and potential challenges to these patents have paved the way for the current generic market.
What are the key challenges and future outlook for S1P receptor modulator patent strategies?
The patenting of S1P receptor modulators is a dynamic area, characterized by rapid innovation and intense competition. Key challenges and future outlook include:
Challenges:
- Navigating Complex Patent Landscapes: The sheer volume of patents surrounding S1P modulators requires extensive due diligence and sophisticated patent analysis for any company developing or investing in this space. Identifying "white space" for innovation and avoiding infringement is difficult.
- Patent Evergreening: Pharmaceutical companies strategically file new patents on existing drugs, covering new formulations, delivery methods, or indications. This practice, often termed "evergreening," aims to extend market exclusivity beyond the original patent term and can be a point of contention with generic manufacturers.
- Litigation Costs and Uncertainty: Patent litigation is costly and unpredictable. Defending patents or challenging those of competitors requires significant legal and financial resources.
- Evolving Regulatory Environment: Changes in patent law and regulatory policies can impact patent enforceability and the timeline for generic entry.
Future Outlook:
- Next-Generation Modulators: Research continues to focus on developing S1P modulators with improved therapeutic indices. This includes compounds with greater selectivity for specific S1P receptor subtypes, potentially offering enhanced efficacy with reduced side effects (e.g., cardiovascular effects, macular edema). Patents will be sought for these novel compounds and their therapeutic uses.
- Broader Therapeutic Applications: The understanding of S1P signaling in various biological processes is expanding. Future patenting efforts are likely to explore new indications for S1P modulators beyond autoimmune diseases, such as in oncology, ophthalmology, and fibrotic diseases.
- Personalized Medicine: As research advances, patents may emerge covering methods of using S1P modulators based on a patient's genetic profile or biomarker status, leading to more personalized treatment strategies.
- Combination Therapies: Patents are expected to be filed for novel combinations of S1P modulators with other drug classes to achieve synergistic therapeutic effects or overcome treatment resistance.
- Biologics and S1P Pathways: While much of the current focus is on small molecule S1P modulators, research into biologics targeting S1P pathways or their downstream effects could also lead to new patentable inventions.
The strategic management of intellectual property, including the careful drafting and aggressive defense of patents, will remain paramount for companies seeking to capitalize on the therapeutic potential of S1P receptor modulation.
Key Takeaways
- U.S. Patent 7,265,009 is foundational for fingolimod's therapeutic use, protecting methods of treating inflammatory conditions via administration of the compound within specific daily dosage ranges.
- The patent's claims are broad, encompassing multiple inflammatory diseases, and its expiry directly influenced the market entry of generic fingolimod.
- The patent landscape for S1P receptor modulators is extensive, characterized by a multi-layered patent strategy by originators and continuous innovation from competitors developing new compounds and indications.
- Biogen's patent portfolio, including 7,265,009, has historically ensured market exclusivity for fingolimod; generic entry signifies the expiration or successful challenge of key patent protections.
- Future patent strategies in the S1P modulator space will likely focus on next-generation compounds, novel therapeutic applications, personalized medicine, and combination therapies.
Frequently Asked Questions
-
When did U.S. Patent 7,265,009 originally expire?
The original expiration date for a U.S. patent is 20 years from the filing date. For U.S. Patent 7,265,009, filed on December 24, 2002, the original expiration would have been December 24, 2022. However, Patent Term Extension (PTE) can extend this period.
-
What is the significance of the dosage range (0.1 mg to 5 mg per day) in Claim 1?
This dosage range defines the specific therapeutic regimen protected by the patent. Any competitor using fingolimod to treat the listed conditions within this dosage range would potentially infringe upon this claim.
-
Does the expiration of U.S. Patent 7,265,009 automatically allow for the sale of generic fingolimod?
No, the expiration of one patent does not automatically permit generic sales. Generic entry requires that all relevant patents, including composition of matter, formulation, and other method-of-use patents, have either expired or been invalidated or found not to be infringed.
-
What are the key S1P receptor subtypes modulated by fingolimod according to the patent?
While the patent mentions S1P receptor modulation broadly, fingolimod is known to act as a functional antagonist on S1P1, S1P3, S1P4, and S1P5 receptors.
-
How does U.S. Patent 7,265,009 differ from a composition of matter patent for fingolimod?
A composition of matter patent protects the chemical compound itself, preventing its unauthorized manufacture, use, or sale. A method of use patent, like 7,265,009, protects a specific way of using that compound for a particular therapeutic purpose.
Citations
[1] Biogen Idec Inc. (2007). U.S. Patent 7,265,009: Methods of Treating Inflammatory Conditions and Related Disorders. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
